A key differentiating factor for donanemab is the drug's finite dosing, which allows patients to stop taking the treatment once brain scans no longer show amyloid plaques.
FDA approves new Alzheimer’s drug that slows memory decline
Read Also
- Israel says negotiators to hold fresh Gaza truce talks next week
- 'We've learnt to do surgery without electricity': Ukraine's power cuts worsen
- Millennium Park renamed Cowboys Park in Calgary’s west downtown
- Donald Trump attempting to claim to ‘know nothing’ about Project 2025
- A dangerous heat wave is scorching much of the U.S. Weather experts predict record-setting temps
- ‘Scared to take the TTC’: Widow speaks out after husband dies in subway station stabbing
- Shell expects to book up to $2 billion in post-tax impairments after delaying construction of a biofuels plant.
- Lithium prices are plumbing multiyear lows in a market awash with the battery material, and it is unlikely they have hit bottom yet.
- Private-equity firm Carlyle Group is in exclusive talks to acquire medical-device maker Baxter's kidney-care spinoff Vantive for more $4 billion, including debt.
- The Nasdaq and S&P 500 gained 0.9% and 0.5% Friday to close out the week at fresh highs while the Dow edged higher after the jobs report shored up hopes that the Fed will cut rates.
Latest Global News
- Millennium Park renamed Cowboys Park in Calgary’s west downtown
- ‘Scared to take the TTC’: Widow speaks out after husband dies in subway station stabbing
- Slow-moving heat wave set to bring record-breaking temperatures across U.S.
- Blue Jays recall Burr, option Cuas to minors
- Partner charged with murder after woman stabbed in south Edmonton
- Edmonton basketball coach charged in connection with alleged sexual assault
- Calgary’s unemployment rate hits 8.5% as poverty gap widens
- Stampede organizers prepared for rain, hail or shine
- Driver rushed to Calgary hospital after truck crashes into building
- Dozens of Stony Plain Road businesses close: ‘Construction needs to be done’